CNK-UT cell therapy for steroid-resistant graft-versus-host disease
Treatments studied
Part of Immune system & allergy clinical trials.
This trial tests a new cell therapy called CNK-UT for people with severe graft-versus-host disease (aGVHD) that hasn't improved with steroid treatment after a stem cell transplant. The goal is to see if it can help control the immune reaction.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 70 years old.
- You have had a stem cell transplant from a donor and developed moderate to severe graft-versus-host disease that didn't get better with steroids.
- You are able to carry out daily activities with some help (ECOG score 0-3).
- You are willing to use effective birth control during the study and for 6 months after treatment.
- You have not had more than one stem cell transplant or an organ transplant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing an investigational cell therapy called NCR102 for people who have severe graft-versus-host disease (a complication after a stem cell transplant) that mainly affects the gut and has not responded to standard treatments. The goal is to see if this new approach is safe and can help control the disease.
This trial tests whether moxibustion—a traditional Chinese medicine technique using heat from burning mugwort—can help treat acute graft-versus-host disease (a complication after bone marrow transplant) that hasn't responded to steroid drugs. If you've had a stem cell transplant and developed this condition that won't go away with standard treatment, this study may be for you.
This study tests a new cell therapy (CK0802) for people with severe graft-versus-host disease (GVHD) that hasn't improved with standard steroid treatment. The treatment aims to control the immune response causing GVHD, potentially reducing symptoms and improving outcomes.
This Phase 1 study tests a new combination of medicines to prevent graft-versus-host disease (GVHD) after an allogeneic stem cell transplant. If it works well, it may lower the chance and severity of GVHD, which can affect skin, liver, and the gut.
This study tests a new cell therapy called GT729 for people with chronic graft-versus-host disease (cGVHD) that hasn't improved with at least two previous treatments. The therapy is given as an injection and aims to help control the immune system reaction that causes cGVHD.
This study tests an experimental cell therapy called VUM02 for people who have graft-versus-host disease (GvHD) after a stem cell transplant that hasn't improved with standard steroid treatment. The goal is to see if this new treatment can help control GvHD symptoms and improve outcomes.
Hear when a new Acute Graft Versus Host Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.